Compare Marathon Digital Holdings Inc (MARA) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Digital Holdings Inc vs Summit Therapeutics Inc — how do they compare? Marathon Digital Holdings Inc trades at $12.26 (market cap $4.45B), while Summit Therapeutics Inc trades at $14.58 (market cap $10.48B). The key difference: Summit Therapeutics Inc is far larger — about 2.4× Marathon Digital Holdings Inc's market cap, and Marathon Digital Holdings Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| MARA | SMMT | |
|---|---|---|
Market Cap | $4.45B | $10.48B |
Sector | Technology | Health |
52-Week High | $22.84 | $29.32 |
52-Week Low | $6.73 | $13.05 |
Enterprise Value | $6.40B | $9.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MARA trades at $11.67, up 9.17% in the last session, but remains in a bearish technical trend. The company reported a net loss of $1.31 billion in 2025 with a negative net margin of 234.83%, though it maintains a high gross margin of 79.22%. Recent news highlights a strategic pivot to AI data centers, including a major Texas land acquisition announced on July 9, 2026, which could add up to 2 GW of power capacity.
The outlook is mixed: analyst consensus is a buy with a $16.90 price target, but significant risks persist from ongoing losses and high volatility. The AI pivot offers growth potential, yet execution and funding challenges pose substantial downside risk for investors.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Marathon Digital Holdings Inc
Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
